Hudbay to Host Conference Call for First Quarter 2024 Results

TORONTO, April 23, 2024 (GLOBE NEWSWIRE) -- Hudbay Minerals Inc. (“Hudbay” or the “company”) (TSX, NYSE: HBM) senior management will host a conference call on Tuesday, May 14, 2024 at 11:00 a.m. ET to discuss the company’s first quarter 2024 results.

Hudbay plans to issue a news release containing the first quarter 2024 results before market open on Tuesday, May 14, 2024 and post it on the company’s website. An archived audio webcast will be available on Hudbay’s website following the call.

About Hudbay

Hudbay (TSX, NYSE: HBM) is a copper-focused mining company with three long-life operations and a world-class pipeline of copper growth projects in tier-one mining-friendly jurisdictions of Canada, Peru and the United States.

Hudbay’s operating portfolio includes the Constancia mine in Cusco (Peru), the Snow Lake operations in Manitoba (Canada) and the Copper Mountain mine in British Columbia (Canada). Copper is the primary metal produced by the company, which is complemented by meaningful gold production. Hudbay’s growth pipeline includes the Copper World project in Arizona (United States), the Mason project in Nevada (United States), the Llaguen project in La Libertad (Peru) and several expansion and exploration opportunities near its existing operations.

The value Hudbay creates and the impact it has is embodied in its purpose statement: “We care about our people, our communities and our planet. Hudbay provides the metals the world needs. We work sustainably, transform lives and create better futures for communities.” Hudbay’s mission is to create sustainable value and strong returns by leveraging its core strengths in community relations, focused exploration, mine development and efficient operations.

For further information, please contact:Candace BrûléVice President, Investor Relations(416) 814-4387[email protected]

You May Also Be Interested In

• HudBay Minerals (HBM) PT Raised to $32 at Barclays
• Update on Investment in Vodafone
• Diagonal Therapeutics Announces First Patient Dosed in Phase 1/2 DIAMOND Clinical Trial of DIAG723 for Hereditary Hemorrhagic Telangiectasia (HHT)